MAPT and Alzheimer disease: CVMs occurring at mid-life appear to work synergistically with age, apolipoprotein E ε4, sex, and amyloid deposition to diminish brain integrity (atrophy, formation of white matter hyperintense lesions, and tau deposition)24–26 and drive cognitive impairment (AD, vascular dementia).